Skip to search formSkip to main contentSkip to account menu

Gleevec

Known as: Glivec 
National Institutes of Health

Related topics

Related topics

4 relations

Broader (2)

Imatinib mesylateimatinib
STI571imatinib 400 MG Oral Tablet [Gleevec]

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2011
Review
2011
Interstitial cells of Cajal in the urinary tract.
The study of novel interstitial cells in the tissues of the urinary tract has defined advances in the field in the last decade… 
Highly Cited
2005
Highly Cited
2005
Imatinib (Gleevec)-induced hepatotoxicity.
Imatinib (Gleevec, Novartis Pharmaceuticals Corp, East Hanover, NJ) is widely used in the treatment of chronic myelogenous… 
2005
2005
Differential molecular response of the transcripts B2A2 and B3A2 to imatinib mesylate in chronic myeloid leukemia.
Chronic myeloid leukemia (CML) originates from the hematopoietic stem cell and is characterized by the reciprocal translocation t… 
Highly Cited
2004
Highly Cited
2004
Extended Follow-up of Patients Treated with Imatinib Mesylate (Gleevec) for Chronic Myelogenous Leukemia Relapse after Allogeneic Transplantation
Purpose: Over the last several years, donor lymphocyte infusions have become the standard approach for patients with chronic… 
2004
2004
Interstitial pneumonia induced by imatinib mesylate: pathologic study demonstrates alveolar destruction and fibrosis with eosinophilic infiltration
Interstitial pneumonia induced by imatinib mesylate: pathologic study demonstrates alveolar destruction and fibrosis with… 
Highly Cited
2003
Highly Cited
2003
Liquid chromatographic-mass spectrometric assay for quantitation of imatinib and its main metabolite (CGP 74588) in plasma.
2003
2003
Squamous cutaneous epithelial cell carcinoma in two CML patients with progressive disease under imatinib treatment
Abstract. Imatinib (glivec®, formerly known as STI571) effectively blocks the ATP‐binding site of the bcr/abl fusion protein… 
Highly Cited
2002
Highly Cited
2002
BCR/ABL amplification in chronic myelocytic leukemia blast crisis following imatinib mesylate administration.
Review
2002
Review
2002
Imatinib and chronic myeloid leukemia: validating the promise of molecularly targeted therapy.
Review
2001
Review
2001
Mechanisms of resistance to imatinib (STI571) and prospects for combination with conventional chemotherapeutic agents.
Imatinib (STI571, Glivec) is a small molecule drug selected for its ability to inhibit the Bcr-Abl kinase, the pathogenic… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)